| Literature DB >> 27814752 |
Linda Johansson1, Natalia Sherina2, Nastya Kharlamova2, Barbara Potempa3, Barbro Larsson2, Lena Israelsson2, Jan Potempa3,4, Solbritt Rantapää-Dahlqvist5, Karin Lundberg2.
Abstract
Entities:
Year: 2016 PMID: 27814752 PMCID: PMC5097366 DOI: 10.1186/s13075-016-1164-1
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Fig. 2Antibody responses during the pre-dating time until the time point for onset of symptoms of RA, from pre-symptomatic individuals who donated multiple blood samples pre-dating the onset of symptoms of RA (n = 422) and from patients with RA (n = 192). Logarithmic mean concentrations during 2-year periods of anti-RgpB and anti-CPP3 antibodies in pre-symptomatic individuals, patients with RA and controls (n = 198) (a). Accumulated percentages of antibody positivity for anti-CPP3, anti-CCP2, anti-cfibrinogenβ36-52 (cFibβ36-52), anti-CEP-1 (α-enolase) and anti-cfilaggrin (cFilaggrin) antibodies in pre-symptomatic individuals and in patients with RA (b). 0 time point for onset of RA symptoms